Federal Social Court

Ruling by German Social Court Supports MyoPro Reimbursement by Nation’s Statutory Health Insurance System

Retrieved on: 
Monday, December 5, 2022
Professional Services, Medical Devices, Health, Health Technology, Insurance, General Health, Lifting, Security (finance), Coronavirus, Arm, EMG, CVA, Risk, Federal Social Court, Patient, Brachial plexus injury, Neuromuscular disease, Massachusetts Institute of Technology, Sale, Spinal cord, Elbow, Paralysis, DAK, NYSE, Hand, ALS, Commission, COVID-19, Annual report, Motion, Harvard Medical School, Marketing, Stroke, Insurance, Health insurance, Medical imaging, Pharmaceutical industry, Risk management

As a result of this ruling, the third-largest German health insurance company, DAK, has been ordered to cover the costs for the MyoPro for the plaintiff.

Key Points: 
  • As a result of this ruling, the third-largest German health insurance company, DAK, has been ordered to cover the costs for the MyoPro for the plaintiff.
  • "With this ruling, a court has confirmed that the MyoPro is a device that can aid patients who suffer from upper extremity impairment and should be covered by statutory health insurance.
  • We expect this ruling will make it easier for patients like the plaintiff to obtain a MyoPro, said John Frijters, Managing Director of Myomo Europe GmbH.
  • The patented MyoPro technology was developed by Myomo in collaboration with researchers at the Massachusetts Institute of Technology and Harvard Medical School.

ReWalk Robotics Files Revised Preliminary Proxy Statement and Issues Letter to Shareholders

Retrieved on: 
Thursday, May 26, 2022
Knowledge, Bring Your Board!!, Company, CMS, Annual general meeting, Emerging technologies, U.S. Securities and Exchange Commission, Healthcare Common Procedure Coding System, Robotics, Annual, Goal, Create, Contract, Solution, Habitat for Humanity, Veterans' affairs, Memorial Day, Association, Stroke, CVC, COVID-19, YOY, Research, FDA, Medicare, Implement, Global Health Innovative Technology Fund, Board, Technology, Senior management, Institution, ReWalk, Adoption, Board of directors, Growth, GLOBE, HCPCS, Annual Meetings of the International Monetary Fund and the World Bank Group, Outline, Medical device, Federal Social Court, Achievement, Management, Sales, Pharmaceutical industry, Health insurance

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 26, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has filed its revised preliminary proxy statement with the U.S. Securities and Exchange Commission (the “SEC”). In connection with this filing, the Company’s Board of Directors (the “Board”) issued the below letter to shareholders.

Key Points: 
  • and BERLIN and YOKNEAM ILIT, Israel, May 26, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (ReWalk or the Company), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has filed its revised preliminary proxy statement with the U.S. Securities and Exchange Commission (the SEC).
  • In connection with this filing, the Companys Board of Directors (the Board) issued the below letter to shareholders.
  • Thank you for your investment in ReWalk Robotics and your confidence in our life-changing technologies.
  • However, we remain open to a continued dialogue in order to avoid a costly, distracting and unnecessary proxy contest that threatens our trajectory.